![](https://ml.globenewswire.com/media/e3cc5e67-fdb7-4440-bc4e-2ab43e8148a5/small/celcuity-logo-jpg.jpg)
Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll first patient in Q2 2025 Expect …